Back to Search
Start Over
[Long-acting beta-2 agonists in pediatric asthma therapy--friend or foe].
- Source :
-
Wiener klinische Wochenschrift [Wien Klin Wochenschr] 2006 Jun; Vol. 118 (11-12), pp. 362-4. - Publication Year :
- 2006
-
Abstract
- Recent publications suggest that long-acting beta-2 agonists (LABAs) increase the risk for death in asthma. The American Food and Drug Administration (FDA) published a relevant alert in 2005. In the currently valid Austrian consensus guidelines for drug therapy of bronchial asthma in children and adolescents, LABAs are only recommended as add-on therapy in those patients whose asthma is not sufficiently controlled by inhaled corticosteroids (ICS) alone. LABAs have no established role in earlier steps of the therapeutic algorithm; consequently, the prescription of ICS-LABA combinations for initial treatment of paediatric asthma is not supported by these consensus treatment guidelines.
- Subjects :
- Austria
Delayed-Action Preparations
Risk Assessment methods
Risk Factors
Adrenergic beta-Agonists adverse effects
Adrenergic beta-Agonists therapeutic use
Anti-Asthmatic Agents adverse effects
Anti-Asthmatic Agents therapeutic use
Asthma drug therapy
Asthma mortality
Practice Guidelines as Topic
Subjects
Details
- Language :
- German
- ISSN :
- 0043-5325
- Volume :
- 118
- Issue :
- 11-12
- Database :
- MEDLINE
- Journal :
- Wiener klinische Wochenschrift
- Publication Type :
- Academic Journal
- Accession number :
- 16855927
- Full Text :
- https://doi.org/10.1007/s00508-006-0607-0